Targeting the mTOR pathway in breast cancer.

about

Allyl Isothiocyanate Exhibits No Anticancer Activity in MDA-MB-231 Breast Cancer Cells.Precision Medicine in Hormone Receptor-Positive Breast Cancer.

P2860

Q47233186-4060EE2E-A584-4DFB-A580-347FC614D05B Q55379220-B99C4408-E660-452C-BFFA-8CE301E31286

P2860

Targeting the mTOR pathway in breast cancer.

Item

http://www.wikidata.org/entity/Q39390640

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Targeting the mTOR pathway in breast cancer.

@en

Targeting the mTOR pathway in breast cancer.

@nl

type

Item

label

Targeting the mTOR pathway in breast cancer.

@en

Targeting the mTOR pathway in breast cancer.

@nl

prefLabel

Targeting the mTOR pathway in breast cancer.

@en

Targeting the mTOR pathway in breast cancer.

@nl

P1476

Targeting the mTOR pathway in breast cancer.

@en

P2093

Fu-Xia Zhou

http://www.w3.org/2001/XMLSchema#string

Hui-Qing Li

http://www.w3.org/2001/XMLSchema#string

Jia Liu

http://www.w3.org/2001/XMLSchema#string

Jie-Wen Yu

http://www.w3.org/2001/XMLSchema#string

Ling Sun

http://www.w3.org/2001/XMLSchema#string

Zhong-Hou Han

http://www.w3.org/2001/XMLSchema#string

P2860

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery

Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling

Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity

mTOR: from growth signal integration to cancer, diabetes and ageing

mTOR signaling in growth control and disease

Differential estradiol and selective estrogen receptor modulator (SERM) regulation of Keratin 13 gene expression and its underlying mechanism in breast cancer cells

Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling

Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer

Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer

Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor

P304

1010428317710825

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1010428317710825

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28639903

http://www.w3.org/2001/XMLSchema#string

Targeting the mTOR pathway in breast cancer.

about

P2860

P2860

Targeting the mTOR pathway in breast cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698